A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.
Also called NCT07116863
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 286 participants
- Sponsor
- Kyungdong Pharmaceutical Co., Ltd.
- Registry
-
NCT07116863
-
- Other papers using this trial's data
- Efficacy and Safety Profile of a Triple Single-Pill Combination of Valsartan/Amlodipine/Chlorthalidone in Patients with Uncontrolled Hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT07116863. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-21 (actual); primary completion 2024-06-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- KDF1901-R0
- Intervention (Drug)
- KDF1901-L
- Intervention (Drug)
- KDF1901
- Intervention (Drug)
- KDF1901-R1
- Lead sponsor
- Kyungdong Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07116863- Content hash
f7f6b3684623c8540cbbd9031a1df660396eaa92fcf4dc921ba4dad1e19a379e